INTRON A (interferon alfa-2b): clinical overview.
D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D007700:Kinetics; D007943:Leukemia, Hairy Cell / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008545:Melanoma / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy; D009369:Neoplasms / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000628:therapy; D011994:Recombinant Proteins / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D012514:Sarcoma, Kaposi / Q000628:therapy; D001749:Urinary Bladder Neoplasms / Q000628:therapy
D007370:Interferon Type I; D011994:Recombinant Proteins